June 11, 2021 10:08 AM EDTUpdated 10:21 AM

Intercept retools C-suite with a pair of newcomers; Charles Ryan moves past Alzheimer's flops with another CEO challenge

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ Jason Campagna and Sandip Kapadia were two execs who punched their tickets out of Intercept as things went pear-shaped, and the teetering NASH biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Intercept retools C-suite with a pair of newcomers; Charles Ryan moves past Alzheimer's flops with another CEO challenge

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Amgen names Stanford geneticist and biotech founder to CSO post

Jazz wins approval for bispecific in biliary tract cancer

Are programs with compounded GLP-1s safe for your population?

In­ter­cept re­tools C-suite with a pair of new­com­ers; Charles Ryan moves past Alzheimer's flops with an­oth­er CEO chal­lenge

Copy Chief

Editor

Sign up to read this article for free.

Intercept retools C-suite with a pair of newcomers; Charles Ryan moves past Alzheimer's flops with another CEO challenge